---
title: "Lysergide (DT120) in Generalized anxiety disorder: Expected outcomes of therapy"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Expected outcomes of therapy. Topics: Summary: symptom change, response, and remission; Summary: onset, durability, and the dosing session; Definitions of response and remission in anxiety disorders; HAM-A severity bands and minimal clinically important difference; 7 further topics. 11 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary: symptom change, response, and remission

In the phase 3 trials, which compared a single dose of DT120 ODT 100 µg with placebo and have reported company topline results, the LS mean HAM-A total score decreased by 11.6 points (Voyage) and 9.8 points (Panorama) at Week 12, compared with 6.2 and 4.7 points with placebo. The placebo-adjusted differences of 5.4 and 5.1 points compare with a minimal clinically important difference of 2.5 points used in the phase 2b trial. At Week 12, 43% (Voyage) and 32% (Panorama) of participants given DT120 had a response (HAM-A improvement of 50% or more) and 14% and 15% a remission (HAM-A of 7 or less), compared with 16% and 14% (response) and 4% and 4% (remission) with placebo. In the phase 2b trial, which used capsules, response at Week 12 occurred in 26 of 40 participants (65.0%) given 100 µg and 12 of 39 (30.8%) given placebo, and remission in 19 (47.5%) and 8 (20.5%).

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-2.2.2.7-2"></a>

### Summary: onset, durability, and the dosing session

Differences from placebo were present early: CGI-S change at Day 2 differed by -0.8 in both phase 3 trials, and HAM-A change at Week 1 by -7.7 (Voyage) and -5.3 (Panorama) points. The controlled comparison covers 12 weeks after one dose. In the 40-week extensions participants could receive open-label DT120 ODT (in Voyage, up to four additional doses based on symptom severity); in interim analyses of partial data (cutoffs July 15, 2026 and August 11, 2026), 60% of 37 Voyage participants and 48% of 27 Panorama participants given DT120 in Part A had a HAM-A response at Week 28. FDA guidance asks sponsors to follow participants beyond Week 12 for symptom recurrence or a need for repeat dosing. Transient perceptual, affective, and emotional effects occurred primarily on the dosing day. Participants were observed by dosing session monitors for at least 8 hours and until they cleared an end-of-session checklist; mean time to clearance was 6.4 hours in Voyage and 6.2 hours in Panorama, and by hour 8, 92% (topline announcement) or 90% (poster) of Voyage participants, 94% of Panorama participants, and 97% across more than 1,000 phase 3 sessions through September 10, 2026 had cleared it. The sponsor states that normal activities, including driving, resume the next day.

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download); [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf); [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.2.2.7-3"></a>

### Definitions of response and remission in anxiety disorders

> “Response is generally regarded as a clinically meaningful improvement in symptoms, while remission, the goal of treatment, is generally thought of as the absence or near absence of symptoms following illness, accompanied by a return to premorbid levels of functioning.”
> “While no universally accepted criteria exist, a commonly used threshold for response is a >50% improvement in the total score, while for remission, various cutoff points have been used.”

Source: [Bandelow (2006)](https://pubmed.ncbi.nlm.nih.gov/17008827/)

<a id="topic-2.2.2.7-4"></a>

### HAM-A severity bands and minimal clinically important difference

> “score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe”
> “The minimal clinically important difference was 2.5 points.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.2.2.7-5"></a>

### Expected HAM-A differences from placebo with existing drugs: network meta-analysis

> “This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.”
> “Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.”
> “Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.7-6"></a>

### Pooled effect sizes of psychotherapy and medication

> “Psychotherapy showed a medium to large effect size (g = 0.76) and medication showed a small effect size (g = 0.38) on GAD outcomes.”
> “Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.”

Source: [Carl et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063818/)

<a id="topic-2.2.2.7-7"></a>

### DT120 in Voyage: response and remission at Week 12

| Outcome at Week 12 | DT120 ODT | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A response rate (≥50%) | “43%” | “16%” | “27% (p<0.0001)” |
| HAM-A remission rate (≤7) | “14%” | “4%” | “10% (p=0.0222)” |

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.2.2.7-8"></a>

### DT120 in Panorama: response and remission at Week 12

| Outcome at Week 12 | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A response rate (≥50%) | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) | “15%” | “4%” | “12% (p<0.05)” |

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.2.2.7-9"></a>

### Durability after a single dose: outcomes beyond Week 12

> “Single dose regimen is being studied in pivotal clinical trials with primary and secondary outcome measures through 12 weeks after administration.”
> “Voyage - HAM-A Scores Improve Further with Additional Treatments in Part B”
> “Based on interim analysis as of July 15, 2026. ITT Part A+B population with treatment policy strategy. Interim analysis based on partial data and subject to change.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.2.2.7-10"></a>

### Durability and repeat dosing: FDA recommendations

> “Although it has been hypothesized that one or a few doses of a psychedelic drug will produce lasting therapeutic benefit, many of the conditions that these drugs are purported to treat typically persist for months or years.”
> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.7-11"></a>

### Expected acute effects on the dosing day

> “Transient clinically significant perceptual, affective, and emotional effects that primarily occurred on dosing day”
> “Clinically insignificant physiological effects”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
